<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590209</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200884</org_study_id>
    <secondary_id>N° IDRCB 2020-A0181336</secondary_id>
    <nct_id>NCT04590209</nct_id>
  </id_info>
  <brief_title>Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome</brief_title>
  <acronym>ACROCOVID</acronym>
  <official_title>Clinical and Mechanistic Study of Patients With a Recent Acrosyndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Cochin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent and unexpected occurrence of patients with the development of skin lesions on the&#xD;
      hands and/ or feet has been described recently. As these cases occurred contemporaneously&#xD;
      with the Coronavirus Disease 2019 (COVID-19) and as it was the most often occurrence of de&#xD;
      novo frostbites, the question raised of whether there is a direct link between the occurrence&#xD;
      of these lesions and infection of the severe acute respiratory syndrome coronavirus 2&#xD;
      (SARS-CoV-2) the responsible for CoVID-19. Indeed, mechanisms of these lesions and the&#xD;
      precise correlation with Sars-CoV-2 remains poorly understood. Therefore, this study aim to:&#xD;
&#xD;
        1. Determine the possible link with this virus,&#xD;
&#xD;
        2. Understand the mechanisms involved in the pathogenesis of these lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigator designed a prospective interventional study in order to&#xD;
      collect blood samples and skin lesion biopsy at significant time points in patients who&#xD;
      present a skin lesion. The intervention in this study is limited to some blood samples and&#xD;
      skin biopsies.&#xD;
&#xD;
      Two 7 mL tubes of blood will be collected at consultant time for essentially serological test&#xD;
      for the SARS-CoV-2 and for analysing certain populations of white blood cells. The second&#xD;
      additional blood sample of 7 mL will be collected around day 15 after inclusion in a dry tube&#xD;
      to perform a serological test for SARS-CoV-2 at a distance from the onset of skin signs.&#xD;
&#xD;
      A biopsy for histological study is usually done in patients with acrosyndrome. This is why&#xD;
      this type of biopsy will be done as a routine care of these patients. An immunohistochemical&#xD;
      study could complete the histological explorations using an anti-coronavirus antibody if&#xD;
      arguments in favour of SARS-CoV-2 are demonstrated. In this study, patients who accept and&#xD;
      sign informed consent will be proposed a skin biopsy on a characteristic lesion for freezing.&#xD;
      This biopsy can be used for transcriptomic analysis. This may allow a better understanding of&#xD;
      the mechanisms of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of SARS-CoV-2 by real-time PCR and serological test</measure>
    <time_frame>assessing change between day 0 and day 15</time_frame>
    <description>SARS-CoV-2 will be tested by Polymorphism Chain Reaction (PCR) (on the first day of consultation) and serological analysis ( at day 0 and day 15 after the first consultation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of SARS-CoV-2 by metagenomics analysis</measure>
    <time_frame>Up to 2.5 months after inclusion</time_frame>
    <description>Metagenomics analysis will be performed on nasopharyngeal, tonsil and perianal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of acrosyndrome by transcriptomic analysis of skin samples</measure>
    <time_frame>Up to 2.5 months after inclusion</time_frame>
    <description>Transcriptomic analysis will be conducted with RNA extracted from frozen skin samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Adult Patients With Lesions on Fingers or Toes</condition>
  <arm_group>
    <arm_group_label>Acrosyndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The blood sample, skin biopsy and other biological samples will be taken from patients&#xD;
The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis</description>
    <arm_group_label>Acrosyndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis</description>
    <arm_group_label>Acrosyndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients&#xD;
&#xD;
          -  Consultant for the recent occurrence of lesions on the fingers and or toes&#xD;
&#xD;
          -  Having signed an informed consent&#xD;
&#xD;
          -  Affiliated or entitled to a social security regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under guardianship or under curate&#xD;
&#xD;
          -  Patients under state medical assistance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sélim Aractingi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tarnier Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Dupin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tarnier Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sélim Aractingi, MD, PhD</last_name>
    <phone>+33158411813</phone>
    <email>selim.aractingi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Benhammani-Godard</last_name>
    <phone>+33158411211</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Tarnier hospital, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sélim Aractingi, MD, PhD</last_name>
      <phone>+33158411813</phone>
      <email>selim.aractingi@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Acrosyndrome</keyword>
  <keyword>Skin lesions</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

